Molecular and Clinical Oncology · 2018 · 17 citations · 21 references
MedicineOncologyBreast OncologyCancer EpidemiologyEpidemiologic MethodsBreast Cancer OncologyBreast PathologyBreast SurgeryCancer Survival AnalysisInflammatory Breast CancerNeoadjuvant TherapyBreast Cancer PrognosisDisease-free Survival AssessmentHistologic GradeHistologic Response AssessmentKaplan-meier Confidence IntervalsMedian AgePrognostic Factors AnalysisRetrospective Case Study
To report epidemiological and anatomo‑clinical features within a retrospective series of inflammatory breast cancer and to evaluate prognostic factors. This retrospective study included 210 Tunisian patients presenting a clinically diagnosed IBC, treated at the Institute Salah Azaiez (ISA) of Tunis, Tunisia, from 2008 to 2013. We collected data on epidemiology, anatomo‑clinical and biological features and histologic response to neoadjuvant therapy. Overall and disease‑free survivals were calculated by Kaplan‑Meier method and compared by log‑rank tests and Cox's models were used to identify prognostic factors impacting survival. The 210 IBC patients had a median age of 42 years (24‑62) and 15% of them were aged less than 35 years. Mean age at menarche was 13 years and 45% had their 1st childbirth before 23 years. On histology, grades III represented 42% of cases, hormone receptors were negative in 59%, HER2 over‑expressed in 32, 25% of our IBC cases had a triple negative profile and Ki‑67 was >20% in 53% of cases. High pathological grade III was significantly correlated to TN subtype (58%) (Fisher's exact test, p=7.5x10‑3). Further, high Ki‑67 expression (>20%) was evident in the TN subtype (84%) (Fisher's exact test, p=3.7x10‑4). After neoadjuvant therapy (and trastuzumab in 88 and 69% of HER2+ patients, respectively), we observed 49% of objective clinical responses and 35% of pathological complete response (pCR) and >3 axillary lymph nodes were invaded on a resected tumor in 55% of cases. Overall survival (OS) was associated with age at menarche (Wald‑test, p=2.2x10‑2) and metastases at diagnosis (Wald‑test, p=2.4x10‑2). Reaching a pCR was correlated with a better metastasis‑free survival (MFS), (Fisher's exact test, p=3.6x10‑2).
21
Giuseppe Viale, Anita Giobbie‐Hurder, Meredith M. Regan et al. · Journal of Clinical Oncology · 2008 · 343 citations · Full text
Medicine, Oncology, Pharmacology +15
Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer
Ismail Jatoi, Susan G. Hilsenbeck, Gary M. Clark et al. · Journal of Clinical Oncology · 1999 · 301 citations
Medicine, Oncology, Breast Oncology +12
Kelly A. Hirko, Amr S. Soliman, Mousumi Banerjee et al. · SpringerPlus · 2013 · 236 citations · Full text
Public Health, Health Sciences, Population Health Sciences +17